[go: up one dir, main page]

WO2010022277A3 - Association de 10-propargyl-10-déazaaminoptérine et de bortézomib pour le traitement de cancers - Google Patents

Association de 10-propargyl-10-déazaaminoptérine et de bortézomib pour le traitement de cancers Download PDF

Info

Publication number
WO2010022277A3
WO2010022277A3 PCT/US2009/054526 US2009054526W WO2010022277A3 WO 2010022277 A3 WO2010022277 A3 WO 2010022277A3 US 2009054526 W US2009054526 W US 2009054526W WO 2010022277 A3 WO2010022277 A3 WO 2010022277A3
Authority
WO
WIPO (PCT)
Prior art keywords
deazaaminopterin
bortezomib
propargyl
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/054526
Other languages
English (en)
Other versions
WO2010022277A2 (fr
Inventor
Owen A. O'connor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2010022277A2 publication Critical patent/WO2010022277A2/fr
Publication of WO2010022277A3 publication Critical patent/WO2010022277A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant du bortézomib et de la 10-propargyl-10-déazaaminoptérine, dans un véhicule pharmaceutiquement acceptable. La présente invention concerne également un procédé de traitement du lymphome des lymphocytes T chez un patient, consistant à administrer simultanément ou séquentiellement au dit patient une quantité thérapeutiquement efficace d’une association comprenant du bortézomib et de la 10-propargyl-10-déazaaminoptérine.
PCT/US2009/054526 2008-08-20 2009-08-20 Association de 10-propargyl-10-déazaaminoptérine et de bortézomib pour le traitement de cancers Ceased WO2010022277A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9051308P 2008-08-20 2008-08-20
US61/090,513 2008-08-20
US11787008P 2008-11-25 2008-11-25
US61/117,870 2008-11-25

Publications (2)

Publication Number Publication Date
WO2010022277A2 WO2010022277A2 (fr) 2010-02-25
WO2010022277A3 true WO2010022277A3 (fr) 2010-06-03

Family

ID=41707665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054526 Ceased WO2010022277A2 (fr) 2008-08-20 2009-08-20 Association de 10-propargyl-10-déazaaminoptérine et de bortézomib pour le traitement de cancers

Country Status (1)

Country Link
WO (1) WO2010022277A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022204368A1 (fr) * 2021-03-24 2022-09-29 Trustees Of Tufts College Composés d'acide boronique, compositions et méthodes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
WO2005117892A1 (fr) * 2004-05-30 2005-12-15 Sloan-Kettering Institute For Cancer Research Traitement du lymphome par la 10-propargyl-10-deazaaminopterine et la gemcitabine
US20060084691A1 (en) * 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
WO2005117892A1 (fr) * 2004-05-30 2005-12-15 Sloan-Kettering Institute For Cancer Research Traitement du lymphome par la 10-propargyl-10-deazaaminopterine et la gemcitabine
US20060084691A1 (en) * 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor

Also Published As

Publication number Publication date
WO2010022277A2 (fr) 2010-02-25

Similar Documents

Publication Publication Date Title
WO2008022256A3 (fr) Procédés et compositions de prévention ou de traitement de maladies liées au vieillissement
WO2008085765A3 (fr) Formes dosifiées de petit volume de médicament contenant du sufentanil s'administrant par voie trans-muqueuse orale pour le traitement de la douleur
WO2012061469A3 (fr) Formes cristallines de pralatrexate
CA2963423A1 (fr) Dispositif et procede pour administrer un medicament
MX2009000745A (es) Dispositivos de suministro transmucosa con admision mejorada.
WO2008131057A3 (fr) Préparations à libération contrôlée d'analgésiques opioïdes et non opioïdes
WO2008131056A3 (fr) Préparations monoeximiques a libération soutenue d'analgésiques opioïdes et non opioïdes
IL245290A0 (en) A medical system for introducing the active substance buprenorphine through the skin
WO2010042471A3 (fr) Dispositifs médicaux pour administration d'agents thérapeutiques à des lumières corporelles
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
WO2007150077A8 (fr) Immunogènes inducteurs de la production de lymphocytes t cytotoxiques utilisables en vue de la prévention, du traitement et du diagnostic du cancer
WO2005081742A3 (fr) Formulations de dosages oraux de testostérone et procédés associés
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
WO2010151503A3 (fr) Multithérapies pour le traitement de l'obésité
WO2007062413A3 (fr) Utilisation d'inhibiteurs du parp-1
WO2007131070A3 (fr) Compositions, formes pharmaceutiques et méthodes de traitement des vomissements
WO2009019708A3 (fr) Compositions pharmaceutiques et procédés pour le traitement du cancer
ATE523200T1 (de) Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
WO2008051527A3 (fr) Libération prolongée d'agents pour la gestion d'une douleur localisée
WO2010045522A3 (fr) Thérapies de combinaison pour le traitement de l'obésité
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
WO2010022277A3 (fr) Association de 10-propargyl-10-déazaaminoptérine et de bortézomib pour le traitement de cancers
WO2010150098A3 (fr) Traitement de l'endométriose
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
WO2009137436A3 (fr) Conjugués peptidiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09808838

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09808838

Country of ref document: EP

Kind code of ref document: A2